EH
Therapeutic Areas
Cerus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INTERCEPT Blood System for Platelets | Pathogen reduction for platelet transfusions | Approved |
| INTERCEPT Blood System for Plasma | Pathogen reduction for plasma transfusions | Approved |
| INTERCEPT Blood System for Cryoprecipitation | Production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex for bleeding in fibrinogen deficiency | Approved |
| INTERCEPT Blood System for Red Blood Cells | Pathogen reduction for red blood cell transfusions | Late-Stage Clinical Development |
Leadership Team at Cerus
W'
William 'Obi' M. Greenman
President and Chief Executive Officer, Chair of the Board
RJ
Richard J. Benjamin
Chief Medical Officer
LM
Laurence M. Corash
Chief Scientific Officer
FW
Frank Witney
Lead Independent Director
JN
Jami Nachtsheim
Board Member, Chair of Nominating & Corporate Governance Committee
AL
Ann Lucena
Board Member
DA
Dean A. Gregory
Board Member
TL
Timothy L. Moore
Board Member
HS
Hua Shan
Board Member